Due to the mutual exclusivity of SMARCA4 and SMARCA2 as catalytic subunits of the SWI/SNF complex, a common approach to targeted treatment of SMARCA4-mutant cancers is synthetic lethality. Here, SMARCA2 is linked to cancer.